![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 44, 34314-34319, November 3, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
,
¶
From the
Department of Pharmacology,
University of Medicine and Dentistry of New Jersey-Robert Wood
Johnson Medical School, Piscataway, New Jersey 08854 and the
§ Regulatory Biology Laboratory, The Salk Institute for
Biological Studies, La Jolla, California 92037
Received for publication, July 28, 2000, and in revised form, August 14, 2000
| |
ABSTRACT |
|---|
|
|
|---|
Human immunodeficiency virus, type 1 (HIV-1), Tat
activates elongation of RNA polymerase II transcription at the HIV-1
promoter through interaction with the cyclin T1 (CycT1) subunit of the positive transcription elongation factor complex, P-TEFb. Binding of
Tat to CycT1 induces cooperative binding of the P-TEFb complex onto
nascent HIV-1 TAR RNA. Here the specific interaction between Tat
protein, human cyclin T1, and HIV-1 TAR RNA was analyzed by fluorescence resonance energy transfer, using fluorescein-labeled TAR
RNA and a rhodamine-labeled Tat protein synthesized through solid-phase
chemistry. We find that CycT1 remodels the structure of Tat to enhance
its affinity for TAR RNA and that TAR RNA further enhances the
interaction between Tat and CycT1. We conclude that TAR RNA nucleates
the formation of the Tat·P-TEFb complex through an induced fit mechanism.
The human immunodeficiency virus
(HIV-1)1 encodes a
transcriptional activator protein, Tat, that increases the processivity of RNA polymerase II (for reviews see Refs. 1-3). Tat activates transcription through binding to the upper stem and bulge region of
TAR, a structured element in the nascent viral RNA, and controls a
DRB-sensitive step early in RNAPII transcription elongation that
results in hyperphosphorylation of the carboxyl-terminal domain (CTD)
of RNA polymerase II. In nuclear extracts, HIV-1 Tat associates tightly
with the CDK9-containing positive transcription elongation factor
complex, P-TEFb (4-6). Recent studies indicate that Tat binds directly
through its trans-activation domain to the cyclin subunit (CycT1) of
the P-TEFb complex and induces loop sequence-specific binding of the
P-TEFb complex to TAR RNA (7-9). Neither CycT1 nor the P-TEFb complex
bind TAR RNA in the absence of Tat, and thus the binding is highly
cooperative for both Tat and P-TEFb (7, 9). The Tat-CycT1
interaction requires zinc as well as cysteine residues in each protein
and therefore may represent a metal-linked heterodimer (8). Tat appears
to contact residues in the carboxyl-terminal boundary of the CycT1
cyclin domain which are not critical for binding of cyclin T1 to CDK9 (8, 10-14), and basic residues in CycT1 (Arg-251 and Arg-254) further stabilize the Tat·P-TEFb·TAR RNA complex (8). Thus the
assembly of this complex appears to involve a series of adaptive interactions between the trans-activation and arginine-rich motif (RNA
binding) domains of Tat and their respective protein (CycT1) and
nucleic acid (TAR) partners during transcription.
These studies have raised the possibility that at least two separate
events may govern the assembly of functional P-TEFb·Tat·TAR complexes. 1) The interaction of Tat with CycT1 induces a
conformational change in Tat that enhances its affinity and kinetic
stability for TAR RNA. 2) TAR RNA may enhance the affinity between
CycT1 and Tat, through an "induced fit" mechanism. These two events would not necessarily be mutually exclusive, and both could contribute significantly to the assembly of a stable ternary complex necessary to
position P-TEFb at the RNA exit channel in a location favorable for
phosphorylation of the RNAPII CTD. To test these hypotheses, we
developed a fluorescence resonance energy transfer (FRET) system containing TAR RNA and Tat protein uniquely labeled with donor and
acceptor dye molecules (Fig. 1). FRET, in
which a fluorescent donor molecule transfers energy via a
non-radioactive dipole-dipole interaction to an acceptor molecule
(which is usually also a fluorescent molecule) is a standard
spectroscopic technique for measuring distances in the 10-70-Å range
(15, 16). The lifetime and quantum yield of the donor are reduced upon
energy transfer, and the acceptor fluorescence is increased or
sensitized. Quantification of the efficiency of energy transfer allows
determination of the distance between the two fluorophores. We used a
well characterized donor-acceptor dye pair, fluorescein-rhodamine, for
FRET experiments. Our results demonstrate that CycT1 enhances the
affinity and kinetic stability of Tat·TAR complex formation. In
addition, it was discovered that TAR RNA enhances CycT1 and Tat
interaction showing how a small RNA hairpin can provide a platform for
protein-protein interactions.
RNA Synthesis--
RNAs were synthesized by chemical and
enzymatic methods. Modified TAR RNA was synthesized on an Applied
Biosystems model 392 DNA/RNA synthesizer using 2-cyanoethyl
phosphoramidite chemistry. All the monomers of (2-cyanoethyl)
phosphoramidites were obtained from Glen Research (Sterling, VA). TAR
RNA was chemically synthesized on a fluorescein-containing CPG 500 support. RNA (1 µmol) containing fluorescein was deprotected by
treatment with NH3-saturated methanol (2 ml) at 25 °C
for 17 h. Product was filtered and dried in Speedvac. To deprotect
2'-OH silyl groups, the red pellet was dissolved in 50%
triethylamine trihydrofluoride in dimethyl sulfoxide (0.5 ml) and left
at room temperature for 16 h. Deprotected RNA was precipitated by
the addition of 2 ml of isopropyl alcohol. After deprotection, RNA was
purified and characterized as described previously (17-19).
Wild-type and mutant TAR RNAs were prepared by in
vitro transcription (20, 21). Enzymatically transcribed RNAs were
5'-dephosphorylated by incubation with calf intestinal alkaline
phosphatase (Promega) for 1 h at 37 °C in 50 mM
Tris-Cl, pH 9.0, 1 mM MgCl2, 0.1 mM ZnCl2, 1 mM spermidine. The RNAs were purified
by multiple extractions with Tris-saturated phenol and one extraction
with 24:1 chloroform:isoamyl alcohol followed by ethanol precipitation.
Chemically synthesized RNA contains only free 3'-OH groups and does not
require dephosphorylation procedures. The RNAs were 5'-end-labeled with
0.5 µM [
The sequence of RNAs was determined by base hydrolysis and nuclease
digestion. Alkaline hydrolysis of RNAs was carried out in hydrolysis
buffer for 8-12 min at 85 °C. RNAs were incubated with 0.1 unit of
RNase from Bacillus cereus (Amersham Pharmacia Biotech) per
picomole of RNA for 4 min at 55 °C in 16 mM sodium citrate, pH 5.0, 0.8 mM EDTA, 0.5 mg/ml yeast tRNA (Life
Technologies, Inc.). This enzyme yields U- and C-specific cleavage of
RNA. Sequencing products were resolved on 20% denaturing gels and
visualized by phosphorimager analysis.
Tat and Cyclin T1 Proteins--
Tat protein (aa 1-72) was
chemically synthesized using standard Fmoc
(N-(9-fluorenyl)methoxycarbonyl) amino acids, and
5-carboxytetramethylrhodamine was incorporated at Lys-19. Details of
Tat-Rhodamine synthesis will be described
elsewhere.2 Rhodamine-labeled
Tat (aa 1-72) was purified by high pressure liquid chromatography and
characterized by mass spectrometry. In vitro transcription
assays and electrophoretic mobility shift experiments showed that the
rhodamine labeling did not significantly alter the structure of Tat
that can interfere with its function (data not shown).
Human CycT1 (aa 1-303 and aa 1-254) was expressed as a glutathione
S-transferase fusion protein, purified, and characterized as
described previously (7, 8).
FRET--
The fluorescence measurements were performed on PTI
fluorescence spectrophotometer controlled by Felix software. The
excitation wavelength was 490 nm and slits width was set 3.5 nm for
both excitation and emission. TAR-fluorescein (200 µl) samples were excited at 490 nm, and the emission intensity was measured at 512 and
575 nm. Measurements were performed in a 200-µl cuvette to reduce the
inner filter effect. The concentrations of TAR RNA-Fl, TAT-Rh and CycT1
(aa 1-303)/Zn2+ were 8.0, 16.5, and 8.0 nM,
respectively. The final concentration of Zn2+ was 0.18 mM. The absorbance of dye-labeled samples were maintained below 0.002 to avoid the inner filter effects. All samples were corrected for the light source excitation effect and for the background intensity of buffer fluorescence as well as for dilution factors. All
experiments were done at room temperature, and the following buffer
conditions were maintained: 50 mM Tris-HCl, pH 7.4, at 25 °C, 20 mM KCl, and 1 mM
For quantitative application of FRET, it is necessary to label RNA
and protein stoichiometrically at unique sites while retaining the
functional properties of biological molecules. Fluorescein-labeled TAR
RNA (TAR RNA-Fl) and rhodamine labeled Tat (Tat-Rh) protein were
chemically synthesized by solid-phase methods. TAR RNA was labeled with
fluorescein at its 3'-end, and rhodamine was incorporated at Lys-19 in
the Tat sequence. We chose Lys-19 in the activation domain of Tat
because it is located in the CycT1-interacting region of Tat and can be
replaced with other amino acids without affecting the function of Tat.
We examined FRET between Tat and TAR in the absence and presence of
cyclin T1. Emission scans were recorded from 500 to 650 nm during the
excitation at 490 nm of TAR RNA-Fl, TAR RNA-Fl with Tat-Rh, and TAR
RNA-Fl, Tat-Rh, and CycT1 (aa 1-303) with Zn2+
(Fig. 2A). TAR RNA-Fl
has an emission maximum around 512 nm (black), whereas upon
adding Tat-Rh (red), this peak is decreased and another peak
at 575 nm is increased. This reduction in fluorescein emission and the
corresponding increase in rhodamine emission were due to the resonance
energy transfer from TAR RNA-Fl to Tat-Rh. However, the presence of
CycT1 (aa 1-303) with Zn2+ (blue) results in a
smaller decrease in the donor fluorescence emission at 512 nm and a
smaller increase at 575 nm in the acceptor fluorescence emission as
compared with TAR RNA-Fl and Tat-Rh. The decrease in the efficiency of
energy transfer in the presence of CycT1 (aa 1-303) and
Zn2+ shows that the distance between the two fluorophores
has increased, indicating that CycT1 induces a conformational change in
Tat structure in a cyclin T1·Tat·TAR ternary complex.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (10K):
[in a new window]
Fig. 1.
A, secondary structure of TAR RNA used
in this study. TAR RNA spans the minimal sequences that are required
for Tat responsiveness in vivo (35) and for in
vitro binding of Tat-derived peptides (36). B, regions
of the HIV-1 Tat (aa 1-72) protein and the position of modification
with rhodamine.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]ATP (6000 Ci/mmol) (ICN)
per 100 pmol of RNA by incubating with 16 units of T4 polynucleotide
kinase (New England Biolabs) in 70 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol (21, 22). The RNAs were labeled at the 3'-end by ligation to cytidine 3',5'-(5'-32P]bisphosphate ([32P]pCp) using
T4 RNA ligase. Reaction mixtures (50 µl) contained 250 pmol of RNA,
65 µCi of [32P]pCp (3000 Ci/mmol, PerkinElmer Life
Sciences), and 40 units of T4 RNA ligase (New England Biolabs) in a
buffer containing 50 mM Tris-HCl, pH 8.0, 3 mM
dithiothreitol, 10 mM MgCl2, 25 mM NaCl, 50 mM ATP, 25 µg/ml bovine serum albumin, and 10%
dimethyl sulfoxide (v/v). After incubation at 4 °C overnight, the
labeled RNAs were purified by phenol/chloroform extraction and ethanol precipitation. 3'- and 5'-end-labeled RNAs were gel-purified on a
denaturing gel, visualized by autoradiography, eluted out of the gels,
and desalted on a reverse-phase cartridge.
-mercaptoethanol.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (17K):
[in a new window]
Fig. 2.
A, fluorescence spectra of TAR
RNA-Fl (black), TAR RNA-Fl with TAT-Rh (red), and
TAR RNA-Fl with TAT-Rh and CycT1 (aa 1-303)/Zn2+
(blue). B, fluorescence titration of TAT-Rh with
8.0 nM TAR RNA-Fl in the absence (squares) and
presence (triangles) of 8.0 nM CycT1 (aa 1-303)
with 0.18 mM Zn2+. Each addition of TAT-Rh was
followed by a 2-min equilibration before the fluorescence signal was
measured. The solid lines represent the best fits of the
data by nonlinear regression to quadratic Equation 1.
Several control experiments further support these observations and demonstrate the specificity of CycT1-Tat-TAR interactions. First, CycT1 (aa 1-303) alone has no effect on the emission spectrum of TAR RNA-Fl (data not shown), an indication of no interaction between these two molecules. Second, in the presence of a truncated CycT1 (aa 1-254), which does not contain Tat-interacting sequences, no specific quenching was observed on either Tat protein or Tat·TAR complex (data not shown). Finally, fluorescence energy transfer was not observed when TAR RNA-Fl was incubated with either free rhodamine dye or unlabeled Tat protein. Wild-type unlabeled TAR RNA successfully competed with the labeled TAR RNA bound to Tat (data no shown), indicating that the fluorescence energy transfer between TAR RNA-Fl and TAT-Rh is due to their specific interactions. These results demonstrate that we have established a specific FRET-based system to study cyclin T1·Tat·TAR ribonucleoprotein complex.
To determine the effect of cyclin T1 on the affinity of Tat for TAR
RNA, we examined fluorescence quenching of TAR RNA-Fl at several
different Tat-Rh concentrations in the absence and presence of CycT1
(aa 1-303). Results of these experiments are shown in Fig.
2B. KD values were calculated by fitting data to quadratic Equation 1,
|
(Eq. 1) |
What is the affinity of CycT1-Tat interactions and does TAR RNA play
any role in this interaction? To address this question, we measured
rhodamine fluorescence quenching at 575 nm by titration of CycT1 (aa
1-303) with Tat-Rh. Fig. 3A
shows the best fit of the data using Equation 1, and a dissociation
constant of 9.1 nM for Tat and CycT1 (aa 1-303) complex
was obtained. To determine the effect of TAR RNA on cyclin T1-Tat
interactions, the same experiments were performed in the presence of
equal molar of unlabeled TAR RNA to TAT-Rh (Fig. 3B). The
dissociation constant for CycT1 (aa 1-303) and Tat in the presence of
TAR was 0.4 nM. These results show that TAR RNA greatly
enhances protein-protein interactions between CycT1 and Tat.
|
An important test of biological significance of ribonucleoprotein
complexes is their kinetic stability, especially in the context of a
vast excess of nonspecific RNA in the cell. The kinetic stability of
the cyclin T1·Tat·TAR complex was determined by forming a complex
between TAR RNA-Fl, Tat-Rh, and CycT1 (aa 1-303), challenging the
complex with an excess of unlabeled competitor and measuring the amount
of remaining complex at different time intervals. Unlabeled TAR RNA
40-100-fold excess over labeled TAR RNA-Fl was used for the
competition. As shown in Fig. 2A, TAR RNA-Fl fluorescence is
quenched by Tat-Rh in a Tat·TAR complex; therefore, addition of
unlabeled competitor would displace Tat-Rh from the complex and would
result in an increase in fluorescence signal of TAR RNA-Fl at 512 nm.
Therefore, the amount of remaining CycT1·Tat·TAR complex can be
assayed by measuring the fluorescence intensity of TAR RNA-Fl at 512 nm. Fig. 4A shows the fraction
of the remaining CycT1·Tat·TAR complex as a function of time when
70-fold excess of unlabeled TAR RNA competitor was added. The
dissociation rate constant (koff) can readily be
obtained by fitting data using Equation 2.
|
(Eq. 2) |
|
In order to test the relationship between koff
and the concentration of competitor, 40-100-fold excess of unlabeled
TAR RNA over labeled TAR RNA were used. The koff
values for CycT1·Tat·TAR complex in the presence of 40-, 70-, and
100-fold competitor RNA were 0.021, 0.034, and 0.09 min
1, respectively. A linear increase of the
dissociation rates of the complex with the increase of the total
competitor concentration was observed (Fig. 4B), which
indicates that the dissociation of the complex is facilitated by
competitor RNA (23). Similar experiments were performed on Tat-Rh and
TAR RNA-Fl complex in the absence of CycT1 which showed that the
complex dissociated with a koff of 0.2 min
1 in the presence of 40-fold competitor
RNA (data not shown). The lifetime of Tat·TAR complex is 5 min, while
under similar conditions CycT1·Tat·TAR complex has a lifetime of 48 min. Therefore, these data indicate that CycT1 enhances the kinetic
stability of the Tat-TAR interactions by ~10-fold. The result that
CycT1 modulates kinetic stability of Tat-TAR interactions may have
great biological implications because a functional ribonucleoprotein
complex must be stable to an overwhelming excess of nonspecific RNA in
the cell.
To determine the conformational changes caused by CycT1 in Tat·TAR
complex, we formed a complex between TAR RNA-Fl and Tat-Rh and
calculated the distance between two fluorophores, rhodamine at Lys-19
of Tat and fluorescein at 3'-end of TAR RNA. The distance (R) between donor, TAR RNA-Fl, and acceptor, TAT-Rh, can be
measured spectroscopically by Förster energy transfer (24). The
distance R was determined from the following equation:
r = R0
(E
1
1)1/6, where
E is the efficiency of nonradioactive transfer. E
was calculated from the quenching of fluorescence emission maximum at
512 nm, i.e. E = (1
IDA/ID), IDA, and ID are the fluorescence intensities at 512 nm in the presence and absence of acceptor, respectively.
R0 = 9786(k2
n
4 Qd
J)1/6A. The donor quantum yield
Qd (0.26) was determined using disodium fluorescein
in 0.1 M NaOH (25), where k represents the
relative orientation of the two fluorophores. Considering a random
orientation of donor and acceptor transition dipoles, k was
assumed to be 2/3 (24). The refractive index of the medium, n, was taken as 1.4 for protein in water.
J(4.46 × 10
13
cm6/mol) is the overlap of the integral and was calculated
from the overlap between the donor emission and acceptor absorbance.
J can be calculated from the sum of the wavelength of
equation J =
(
A(
)
FD(
)
4

)/
FD(
), where
A(
) and
FD(
) are the extinction coefficient of acceptor
and the intensity of fluorescence emission of donor, respectively. The
fluorescence intensity of the TAR RNA-Fl in the presence of TAT-Rh was
used to calculate the distance between the two fluorophores. The
efficiency of energy transfer (E) is shown in Fig.
5. The efficiency of transfer between
TAR-Fl and TAT-Rh was 25% (Table I).
However, in the presence of CycT1 (aa 1-303) and 0.18 mM
Zn2+, the efficiency of energy transfer was decreased to
15% (Table I). The distance (R) between two fluorophores
was determined from R0 and E that
showed that Lys-19 rhodamine in Tat is 57.2 Å apart from fluorescein
at the 3'-end of TAR RNA, and this distance was changed to 63.6 Å in
the presence of CycT1-(1-303). Since Lys-19-rhodamine is located in
the CycT1-interacting region of Tat, these results indicate that Tat
goes through a structural reorganization upon CycT1 binding (Fig.
5).
|
|
Interestingly, when Zn2+ was removed from the binding reactions, no energy transfer was detected. This result supports a previously proposed model for cyclin T1-Tat-TAR interactions suggesting that Tat forms a metal-linked heterodimer with cyclin T1 (8).
We find that Tat (aa 1-72) binds TAR RNA with a KD of 8.2 nM and that this affinity is enhanced 10-fold in the presence of CycT1 (aa 1-303). Taken together with the changes in the relative location of Tat on TAR when bound to CycT1, we infer that CycT1 enhances the affinity and stability of the Tat·TAR complex in a manner that is accompanied by a significant conformational change in the structure of the Tat protein. In addition, a Tat peptide containing only the arginine-rich motif, Tat (aa 49-57), binds TAR with a KD of 1 nM, whereas a longer peptide containing additional amino acids from the core domain, Tat(aa 38-72), has a lower affinity for TAR RNA with a KD of 5.7 nM.3 The observation that the isolated arginine-rich motif of Tat binds much more tightly to TAR RNA than Tat proteins containing the activation domain has also been observed with the native full-length (86 aa) HIV-1 and (130 aa) HIV-2 Tat proteins (9) and suggests an autoinhibitory mechanism in which intramolecular interactions involving residues that overlap the activation domain effectively block binding to TAR RNA in the absence of CycT1. Interaction with CycT1 overcomes this inhibitory effect and permits high affinity binding of residues in the arginine-rich motif to TAR RNA. Although intramolecular masking is a well characterized feature of DNA-binding enhancer factors such as Ets-1 and p53 (26-28), to our knowledge it has not been reported previously in sequence-specific RNA-binding proteins. Autoinhibition could serve an important mechanism to ensure that Tat will not bind TAR RNA without first interacting with CycT1 in the P-TEFb complex, and free uncomplexed Tat protein may be unstable and subject to rapid turnover by cellular proteases, as has been suggested for other unstructured transcriptional regulators (reviewed in Ref. 29), thus providing the virus a mechanism to restrict the level of nonfunctional Tat in infected cells.
Importantly, we also find that TAR RNA strongly enhances the
interaction between Tat and CycT1. RNA-induced protein-protein interactions have been most clearly documented with the
N protein, which binds to a site in the box B RNA to mediate transcriptional anti-termination (30-33). Recent models suggest that the N protein induces a restructuring of residues in the loop of the box B RNA hairpin loop to provide a platform for the subsequent loading of the
NusA protein (31-33), suggesting that the interaction of N with
box B RNA enhances the weak protein-protein interaction that is
otherwise observed between N and NusA (reviewed in Ref. 29). The
regulation of protein interaction through structural alterations in the
RNA could be an important mechanism for controlling the order of
assembly of the Tat·P-TEFb·TAR complex both to ensure that Tat will
not commit to TAR in the absence of CycT1(P-TEFb) and, similarly, to
ensure that P-TEFb is preferentially utilized at the viral promoter,
since cellular genes do not express TAR RNA. The ability to remodel a
transcriptional activator through interaction with protein and nucleic
acids partners could also be important for exchanging Tat protein with
other possible partners. Thus, after phosphorylation of the RNAPII CTD,
Tat has been shown to interact with RNA polymerase II rather than TAR
(34). The mechanism that controls the disassembly of the stable
Tat·P-TEFb·TAR complex is unknown but may rely on the ability of
the Tat protein to model itself to available surfaces on the RNA
polymerase elongation complex. These findings with the Tat and
N
proteins highlight the versatility of RNA as an enhancer of specific
protein-protein interactions.
| |
FOOTNOTES |
|---|
* This work was supported in part by National Institutes of Health Grant AI 41404 (to T. M. R.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Recipient of a Research Career Development award from the National Institutes of Health. To whom correspondence should be addressed: Dept. of Pharmacology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Ln., Piscataway, NJ 08854. Tel.: 732-235-4082; Fax: 732- 235-3235; E-mail: rana@umdnj.edu.
Published, JBC Papers in Press, August 15, 2000, DOI 10.1074/jbc.M006804200
2 N. Tamilarasu and T. M. Rana, unpublished data.
3 J. Zhang, N. Tamilarasu, S. Hwang, and T. M. Rana, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
HIV-1, human
immunodeficiency virus, type 1;
DRB, 5,6-dichloro-1-
-D-ribofuranosylbenzimidazole;
aa, amino acid(s);
CTD, carboxyl-terminal domain;
CycT1, cyclin T1;
FRET, fluorescence resonance energy transfer.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Jones, K. A. (1997) Genes Dev. 11, 2593-2599 |
| 2. | Cullen, B. R. (1998) Cell 93, 685-692 |
| 3. | Emerman, M., and Malim, M. (1998) Science 280, 1880-1884 |
| 4. | Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M. B., and Price, D. H. (1997) Genes Dev. 11, 2622-2632 |
| 5. | Mancebo, H. S. Y., Lee, G., Flygare, J., Tomassini, J., Luu, P., Zhu, Y., Peng, J., Blau, C., Hazuda, D., Price, D., and Flores, O. (1997) Genes Dev. 11, 2633-2644 |
| 6. | Gold, M., Yang, X., Herrmann, C., and Rice, A. (1998) J. Virol. 72, 4448-4453 |
| 7. | Wei, P., Garber, M. E., Fang, S.-M., Fischer, W. H., and Jones, K. A. (1998) Cell 92, 451-462 |
| 8. | Garber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Herrmann, C. H., Rice, A. P., Littman, D. R., and Jones, K. A. (1998) Genes Dev. 12, 3512-3527 |
| 9. | Garber, M. E., Wei, P., and Jones, K. A. (1998) Cold Spring Harbor Symp. Quant. Biol. 63, 371-380 |
| 10. | Bieniasz, P. D., Grdina, T. A., Bogerd, H. P., and Cullen, B. R. (1998) EMBO J. 17, 7056-7065 |
| 11. | Fujinaga, K., Cujec, T., Peng, J., Garriga, J., Price, D., Grana, X., and Peterlin, B. (1998) J. Virol. 72, 7154-7159 |
| 12. | Wimmer, J., Fujinaga, K., Taube, R., Cujec, T., Zhu, Y., Peng, J., Price, D., and Peterlin, B. (1999) Virology 255, 182-189 |
| 13. | Ivanov, D., Kwak, Y. T., Nee, E., Guo, J., Garcia-Martinez, L. F., and Gaynor, R. B. (1999) J. Mol. Biol. 288, 41-56 |
| 14. | Zhou, Q., Chen, D., Pierstorff, E., and Luo, K. (1998) EMBO J. 17, 3681-3691 |
| 15. | Clegg, R. M. (1992) Methods Enzymol. 211, 353-388 |
| 16. | Yang, M., and Millar, D. P. (1997) Methods Enzymol. 278, 417-444 |
| 17. | Shah, K., Wu, H., and Rana, T. M. (1994) Bioconjugate Chem. 5, 508-512 |
| 18. | Shah, K., Neenhold, H., Wang, Z., and Rana, T. M. (1996) Bioconjugate Chem. 7, 283-289 |
| 19. | Ping, Y.-H., Liu, Y., Wang, X., Neenhold, H. R., and Rana, T. M. (1997) RNA (NY) 3, 850-860 |
| 20. | Milligan, J. F., Groebe, D. R., Witherell, G. W., and Uhlenbeck, O. C. (1987) Nucleic Acids Res. 15, 8783-8798 |
| 21. | Wang, Z., and Rana, T. M. (1996) Biochemistry 35, 6491-6499 |
| 22. | Neenhold, H. R., and Rana, T. M. (1995) Biochemistry 34, 6303-6309 |
| 23. | Fried, M., and Crothers, D. M. (1981) Nucleic Acids Res. 9, 6505-6525 |
| 24. | Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , pp. 303-336, Plenum Publishing Corp., New York |
| 25. | Weber, G., and Teale, F. W. J. (1957) Trans. Faraday Soc. 53, 646-655 |
| 26. | Jonsen, M. D., Petersen, J. M., Xu, Q.-P., and Graves, B. J. (1996) Mol. Cell. Biol. 16, 2065-2073 |
| 27. | Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. (1992) Cell 71, 875-886 |
| 28. | Halazonetis, T. D., and Kandil, A. N. (1993) EMBO J. 12, 5057-5064 |
| 29. | Frankel, A. D., and Smith, C. A. (1998) Cell 92, 149-151 |
| 30. | Van Gilst, M. R., Rees, W. A., Das, A., and von Hippel, P. H. (1997) Biochemistry 36, 1514-1524 |
| 31. | Su, L., Radek, J. T., Labeots, L. A., Hallengra, K., Hermanto, P., Chen, H., Nakagawa, S., Zhao, M., Kates, S., and Weiss, M. A. (1997) Genes Dev. 11, 2214-2226 |
| 32. | Legault, P., Li, J., Mogridge, J., Kay, L. E., and Greenblatt, J. (1998) Cell 93, 289-299 |
| 33. | Mogridge, J., Legault, P., Li, J., Van Oene, M. D., Kay, L. E., and Greenblatt, J. (1998) Mol. Cell 1, 265-275 |
| 34. | Keen, N. J., Churcher, M. J., and Karn, J. (1997) EMBO J. 16, 5260-5272 |
| 35. | Jakobovits, A., Smith, D. H., Jakobovits, E. B., and Capon, D. J. (1988) Mol. Cell. Biol. 8, 2555-2561 |
| 36. | Cordingley, M. G., La Femina, R. L., Callahan, P. L., Condra, J. H., Sardana, V. V., Graham, D. J., Nguyen, T. M., Le Grow, K., Gotlib, L., Schlabach, A. J., and Colonno, R. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8985-8989 |
This article has been cited by other articles:
![]() |
M. Barboric, J. H. N. Yik, N. Czudnochowski, Z. Yang, R. Chen, X. Contreras, M. Geyer, B. Matija Peterlin, and Q. Zhou Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription Nucleic Acids Res., March 19, 2007; 35(6): 2003 - 2012. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Egloff, E. Van Herreweghe, and T. Kiss Regulation of Polymerase II Transcription by 7SK snRNA: Two Distinct RNA Elements Direct P-TEFb and HEXIM1 Binding Mol. Cell. Biol., January 15, 2006; 26(2): 630 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O'Gorman, B. Thomas, K. Y. Kwek, A. Furger, and A. Akoulitchev Analysis of U1 Small Nuclear RNA Interaction with Cyclin H J. Biol. Chem., November 4, 2005; 280(44): 36920 - 36925. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schulte, N. Czudnochowski, M. Barboric, A. Schonichen, D. Blazek, B. M. Peterlin, and M. Geyer Identification of a Cyclin T-Binding Domain in Hexim1 and Biochemical Analysis of Its Binding Competition with HIV-1 Tat J. Biol. Chem., July 1, 2005; 280(26): 24968 - 24977. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Parent, T. M. C. Yung, A. Rancourt, E. L. Y. Ho, S. Vispe, F. Suzuki-Matsuda, A. Uehara, T. Wada, H. Handa, and M. S. Satoh Poly(ADP-ribose) Polymerase-1 Is a Negative Regulator of HIV-1 Transcription through Competitive Binding to TAR RNA with Tat{middle dot}Positive Transcription Elongation Factor b (p-TEFb) Complex J. Biol. Chem., January 7, 2005; 280(1): 448 - 457. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Xie, V. Calabro, M. A. Wainberg, and A. D. Frankel Selection of TAR RNA-Binding Chameleon Peptides by Using a Retroviral Replication System J. Virol., February 1, 2004; 78(3): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kulinski, M. Olejniczak, H. Huthoff, L. Bielecki, K. Pachulska-Wieczorek, A. T. Das, B. Berkhout, and R. W. Adamiak The Apical Loop of the HIV-1 TAR RNA Hairpin Is Stabilized by a Cross-loop Base Pair J. Biol. Chem., October 3, 2003; 278(40): 38892 - 38901. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hwang, N. Tamilarasu, K. Kibler, H. Cao, A. Ali, Y.-H. Ping, K.-T. Jeang, and T. M. Rana Discovery of a Small Molecule Tat-trans-Activation-responsive RNA Antagonist That Potently Inhibits Human Immunodeficiency Virus-1 Replication J. Biol. Chem., October 3, 2003; 278(40): 39092 - 39103. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Michels, V. T. Nguyen, A. Fraldi, V. Labas, M. Edwards, F. Bonnet, L. Lania, and O. Bensaude MAQ1 and 7SK RNA Interact with CDK9/Cyclin T Complexes in a Transcription-Dependent Manner Mol. Cell. Biol., July 15, 2003; 23(14): 4859 - 4869. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Holmes, A. A. Arzumanov, and M. J. Gait Steric inhibition of human immunodeficiency virus type-1 Tat-dependent trans-activation in vitro and in cells by oligonucleotides containing 2'-O-methyl G-clamp ribonucleoside analogues Nucleic Acids Res., June 1, 2003; 31(11): 2759 - 2768. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. R. K. Yedavalli, M. Benkirane, and K.-T. Jeang Tat and Trans-activation-responsive (TAR) RNA-independent Induction of HIV-1 Long Terminal Repeat by Human and Murine Cyclin T1 Requires Sp1 J. Biol. Chem., February 14, 2003; 278(8): 6404 - 6410. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Lee, H. Kim, J. Ko, and Y. Lee Interaction of C5 protein with RNA aptamers selected by SELEX Nucleic Acids Res., December 15, 2002; 30(24): 5360 - 5368. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fujinaga, D. Irwin, R. Taube, F. Zhang, M. Geyer, and B. M. Peterlin A Minimal Chimera of Human Cyclin T1 and Tat Binds TAR and Activates Human Immunodeficiency Virus Transcription in Murine Cells J. Virol., November 13, 2002; 76(24): 12934 - 12939. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. K. Kim, C. F. Bourgeois, C. Isel, M. J. Churcher, and J. Karn Phosphorylation of the RNA Polymerase II Carboxyl-Terminal Domain by CDK9 Is Directly Responsible for Human Immunodeficiency Virus Type 1 Tat-Activated Transcriptional Elongation Mol. Cell. Biol., July 1, 2002; 22(13): 4622 - 4637. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Richter, Y.-H. Ping, and T. M. Rana TAR RNA loop: A scaffold for the assembly of a regulatory switch in HIV replication PNAS, June 11, 2002; 99(12): 7928 - 7933. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hoque, T. M. Young, C.-G. Lee, G. Serrero, M. B. Mathews, and T. Pe'ery The Growth Factor Granulin Interacts with Cyclin T1 and Modulates P-TEFb-Dependent Transcription Mol. Cell. Biol., March 1, 2002; 23(5): 1688 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marcello, R. A. G. Cinelli, A. Ferrari, A. Signorelli, M. Tyagi, V. Pellegrini, F. Beltram, and M. Giacca Visualization of in Vivo Direct Interaction between HIV-1 TAT and Human Cyclin T1 in Specific Subcellular Compartments by Fluorescence Resonance Energy Transfer J. Biol. Chem., October 12, 2001; 276(42): 39220 - 39225. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||